None listed
Conditions
Brief summary
The aim of this study is to determine the feasibility, safety, and acceptability of short-term humidified flow therapy (myAirvo 3TM) in people living with respiratory conditions in the SESLHD community. The hypothesis is that myAirvo 3 is feasible, safe and acceptable to be used in the community and will assist sputum burden and/or breathlessness.
Interventions
myAirvo 3TM (Fisher & Paykel) is a non-invasive respiratory support that provides flow from 2-60 L/min and delivers heated (up to 38°C) and humidified (100% relative humidity) air via a nasal cannula, with supplemental oxygen as required.
Participants will have an individualised dose of oxygen only as prescribed by their Respiratory Physician and if required.
Participants will be able to use myAirvo 3TM at home. Participants will be advised to use myAirvo 3TM for at least one hour a day for 28 d
myAirvo 3TM (Fisher & Paykel) is a non-invasive respiratory support that provides flow from 2-60 L/min and delivers heated (up to 38°C) and humidified (100% relative humidity) air via a nasal cannula, with supplemental oxygen as required. Participants will have an individualised dose of oxygen only as prescribed by their Respiratory Physician and if required. Participants will be able to use myAirvo 3TM at home. Participants will be advised to use myAirvo 3TM for at least one hour a day for 28 days. Registered Nurses, Respiratory Physiotherapists, Respiratory Registrars and Physicians, will administer the intervention. Adherence to the intervention will be monitored remotely via myAirvo 3TM.
Sponsors
The Sutherland Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- greater than or equal to 18 years of age - MMSE > 24 - Has sputum burden and/or breathlessness and a diagnosed chronic respiratory condition - Known to The Sutherland Hospital Respiratory Coordinated Care Program - Willingness to give written informed consent
Exclusion criteria
- < 18 years of age - MMSE greater than or equal to 24 - Unable to tolerate a nasal cannula - Patients with a history of type 2 respiratory failure - Unable to safely set up and use the device at home - Has not given written informed consent
Outcome results
None listed